(Q36482909)

14 August 2017

1 reference

title

Metabolic considerations in the choice of therapy for the patient with hypertension (English)

1 reference

14 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671190

Cardiology and cardiovascular medicine

25 October 2022

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

25 October 2022

author name string

H. R. Black

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671190

25 October 2022

language of work or name

English

0 references

publication date

1 February 1991

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:000287039190451M?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

https://api.elsevier.com/content/article/PII:000287039190451M?httpAccept=text/plain

25 October 2022

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

25 October 2022

published in

American Heart Journal

1 reference

14 August 2017

volume

121

1 reference

14 August 2017

issue

2 Pt 2

1 reference

14 August 2017

page(s)

707-715

1 reference

Status of risk factors and their consideration in antihypertensive therapy

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials

25 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Blood pressure, stroke, and coronary heart disease

25 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

25 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Calcium channel blockers. Potential medical benefits and side effects.

25 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review.

25 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Hormonal and metabolic effects of calcium channel antagonists in man.

25 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Clinical and Hemodynamic Effects of Celiprolol in Essential Hypertension

25 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism

25 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Diuretic-induced ventricular ectopic activity

25 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Thiazide Therapy Is Not a Cause of Arrhythmia in Patients With Systemic Hypertension

25 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Hypokalaemia and ventricular fibrillation in acute myocardial infarction

25 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Initial serum potassium level in relation to early complications and prognosis in patients with acute myocardial infarction

25 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Effects of reduction in dose and discontinuation of hydrochlorothiazide in patients with controlled essential hypertension

25 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy

25 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Diuretic-induced hyponatremia

25 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Antihypertensive treatment and serum lipoproteins

25 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial

25 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

25 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah

25 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia

25 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

25 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Diuretics in the management of hypertension.

25 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Role of diuretics in treatment of essential hypertension

25 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Effects of diuretic drugs on the lipid profile

25 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Recent studies on the effects of beta blockers on blood lipid levels

25 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up

25 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension

25 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Insulin resistance in essential hypertension

25 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Insulin resistance is a characteristic feature of primary hypertension independent of obesity.

25 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Banting lecture 1988. Role of insulin resistance in human disease

25 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension

25 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Hyperinsulinemia. A link between hypertension obesity and glucose intolerance

25 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Recent studies on the effects of beta blockers on blood lipid levels

25 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Effects of antihypertensive drugs on plasma lipids

25 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol

25 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol

25 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors.

25 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

25 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group

25 October 2022

55

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial

25 October 2022

56

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results

25 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

25 October 2022

58

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Do antihypertensive drugs precipitate diabetes in predisposed men?

25 October 2022

60

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Diabetes in patients with hypertension receiving pharmacological treatment

25 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients

25 October 2022

62

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups.

25 October 2022

63

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Safety profile of celiprolol

25 October 2022

64

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Angiotensin converting enzyme inhibitors. II. Clinical use.

25 October 2022

65

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

The effect of captopril and metoprolol as monotherapy or combined with bendroflumethiazide on blood lipids

25 October 2022

66

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Use of captopril to reduce serum lipids in hypertensive patients with hyperlipidemia

25 October 2022

67

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension

25 October 2022

68

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension

25 October 2022

70

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Choosing initial therapy for hypertension. A personal view.

25 October 2022

71

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Enalapril in essential hypertension

25 October 2022

73

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

Hypolipidemic effects of long-term antihypertensive treatment with captopril. A prospective study

25 October 2022

74

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90451-M

25 October 2022

Identifiers

1 reference

14 August 2017

1 reference